Skip to main content

Axis Bank Q2 Preview: NII may grow over 15% with 10% loan growth, asset quality key

HDFC Securities expects around 10 percent YoY loan growth and a marginal improvement in NIMs to drive core earnings (NII) growth of 16 percent YoY.

Private sector lender Axis Bank is expected to report a profit in the range of Rs 1,400-2,000 crore during Q2FY21 against a loss of Rs 112.1 crore in the year-ago quarter. The lender is also likely to report a sharp sequential growth in profit to lower provisions.

Net interest income (NII), the difference between the interest income from lending activities and the interest paid to depositor, is seen rising more than 15 percent year-on-year with 10 percent loan growth and 11 percent growth in deposits compared to the year-ago period, while pre-provision operating profit may grow in the 6-8 percent range YoY.



"We expect loan growth at 10 percent YoY with a greater focus on retail. We expect operating profit to grow at 8 percent YoY led by better cost controls," said Kotak Institutional Equities, which sees profit at Rs 1,982 crore and 17.5 percent growth in NII.

HDFC Securities sees around 10 percent YoY loan growth and a marginal improvement in NIMs are expected to drive core earnings (NII) growth of 16 percent YoY.

Asset quality is expected to be largely stable on a sequential basis with the focus on the quantum of loan restructuring but credit cost may stay higher.

"We expect slippages of around Rs 2,500 crore (around 2 percent of loans) subject to a court ruling. We expect gross NPL to remain flat QoQ. The focus would be on the expected quantum of restructured loans by Q4FY21 and update on the loan book as the moratorium is lifted," Kotak said.

KR Choksey expects the credit costs to remain elevated and the focus to remain on restructuring.

 

Comments

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...

Taking Stock | Profit-booking pulls Nifty below 14,450; Sensex drops 549 points

  All the sectoral indices ended in the red with IT and PSU bank indices falling 2 percent each. The market remained under pressure on January 15 on the back of profit-booking across sectors amid weak global cues. At close, the Sensex was down 549.49 points or 1.11% at 49,034.67, and Nifty was down 161.90 points or 1.11% at 14,433.70. "The market witnessed profit-booking and following global trends. Nifty continues to resist 14,600 and has taken a dip towards 14,360. If the market closes below 14,380 levels, we might see a correction till the levels of 14,180-14,200. Momentum indicators like RSI, MACD are indicating a small correction in the markets," said Ashis Biswas, Head of Research at CapitalVia Global Research. All the sectoral indices ended in the red with IT and PSU bank falling 2 percent each. Broader markets performed in line with the main indices with BSE Midcap and Smallcap indices falling 1 percent each. Tech Mahindra, GAIL, HCL Tech, Wipro and ONGC...